19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations

István Molnár, Timothy Kute, Mark C. Willingham, Gary G. Schwartz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved in the United States for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has anticancer activity in prostate cancer cells. We tested the effects of paricalcitol on the HL-60 leukemia cells, studying cellular differentiation, cell cycle changes, apoptosis and cellular proliferation. Paricalcitol at 10-8 M concentration induced the maturation of HL-60 cells in a time-dependent manner, as shown by increased expression of CD11b differentiation surface antigen. The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was markedly increased after exposure to paricalcitol at 10-8 M for 72 h. Paricalcitol inhibited colony formation of HL-60 cells in a soft agar semisolid media after 10-day incubation (estimated IC50 of 5×10-9 M. Exposure to 10 -8M paricalcitol for 72 h increased the number of cells in G 0/G1 phase, and decreased the number of cells in S phase, and significantly increased the number of HL-60 cells undergoing apoptosis. The concentration required to achieve inhibition of growth of HL-60 cells is comparable to clinically achievable levels. These findings support the clinical evaluation of paricalcitol as an antileukemia agent.

Original languageEnglish (US)
Pages (from-to)539-543
Number of pages5
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume89-90
DOIs
StatePublished - May 1 2004

Fingerprint

HL-60 Cells
CD11b Antigens
Cell Count
Cells
Apoptosis
Nitroblue Tetrazolium
Gastrin-Secreting Cells
In Vitro Techniques
1,25-dihydroxyergocalciferol
paricalcitol
Differentiation Antigens
G1 Phase
Surface Antigens
Parathyroid Hormone
S Phase
Inhibitory Concentration 50
Chronic Kidney Failure
Agar
Prostatic Neoplasms
Cell Cycle

Keywords

  • Apoptosis
  • Differentiation
  • Experimental therapeutics
  • HL-60
  • Paricalcitol

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations. / Molnár, István; Kute, Timothy; Willingham, Mark C.; Schwartz, Gary G.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 89-90, 01.05.2004, p. 539-543.

Research output: Contribution to journalArticle

@article{0fe93bfca85f43948ef16dc9c8cb1b00,
title = "19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations",
abstract = "19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved in the United States for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has anticancer activity in prostate cancer cells. We tested the effects of paricalcitol on the HL-60 leukemia cells, studying cellular differentiation, cell cycle changes, apoptosis and cellular proliferation. Paricalcitol at 10-8 M concentration induced the maturation of HL-60 cells in a time-dependent manner, as shown by increased expression of CD11b differentiation surface antigen. The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was markedly increased after exposure to paricalcitol at 10-8 M for 72 h. Paricalcitol inhibited colony formation of HL-60 cells in a soft agar semisolid media after 10-day incubation (estimated IC50 of 5×10-9 M. Exposure to 10 -8M paricalcitol for 72 h increased the number of cells in G 0/G1 phase, and decreased the number of cells in S phase, and significantly increased the number of HL-60 cells undergoing apoptosis. The concentration required to achieve inhibition of growth of HL-60 cells is comparable to clinically achievable levels. These findings support the clinical evaluation of paricalcitol as an antileukemia agent.",
keywords = "Apoptosis, Differentiation, Experimental therapeutics, HL-60, Paricalcitol",
author = "Istv{\'a}n Moln{\'a}r and Timothy Kute and Willingham, {Mark C.} and Schwartz, {Gary G.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1016/j.jsbmb.2004.03.064",
language = "English (US)",
volume = "89-90",
pages = "539--543",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations

AU - Molnár, István

AU - Kute, Timothy

AU - Willingham, Mark C.

AU - Schwartz, Gary G.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved in the United States for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has anticancer activity in prostate cancer cells. We tested the effects of paricalcitol on the HL-60 leukemia cells, studying cellular differentiation, cell cycle changes, apoptosis and cellular proliferation. Paricalcitol at 10-8 M concentration induced the maturation of HL-60 cells in a time-dependent manner, as shown by increased expression of CD11b differentiation surface antigen. The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was markedly increased after exposure to paricalcitol at 10-8 M for 72 h. Paricalcitol inhibited colony formation of HL-60 cells in a soft agar semisolid media after 10-day incubation (estimated IC50 of 5×10-9 M. Exposure to 10 -8M paricalcitol for 72 h increased the number of cells in G 0/G1 phase, and decreased the number of cells in S phase, and significantly increased the number of HL-60 cells undergoing apoptosis. The concentration required to achieve inhibition of growth of HL-60 cells is comparable to clinically achievable levels. These findings support the clinical evaluation of paricalcitol as an antileukemia agent.

AB - 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved in the United States for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has anticancer activity in prostate cancer cells. We tested the effects of paricalcitol on the HL-60 leukemia cells, studying cellular differentiation, cell cycle changes, apoptosis and cellular proliferation. Paricalcitol at 10-8 M concentration induced the maturation of HL-60 cells in a time-dependent manner, as shown by increased expression of CD11b differentiation surface antigen. The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was markedly increased after exposure to paricalcitol at 10-8 M for 72 h. Paricalcitol inhibited colony formation of HL-60 cells in a soft agar semisolid media after 10-day incubation (estimated IC50 of 5×10-9 M. Exposure to 10 -8M paricalcitol for 72 h increased the number of cells in G 0/G1 phase, and decreased the number of cells in S phase, and significantly increased the number of HL-60 cells undergoing apoptosis. The concentration required to achieve inhibition of growth of HL-60 cells is comparable to clinically achievable levels. These findings support the clinical evaluation of paricalcitol as an antileukemia agent.

KW - Apoptosis

KW - Differentiation

KW - Experimental therapeutics

KW - HL-60

KW - Paricalcitol

UR - http://www.scopus.com/inward/record.url?scp=3042647149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042647149&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2004.03.064

DO - 10.1016/j.jsbmb.2004.03.064

M3 - Article

C2 - 15225834

AN - SCOPUS:3042647149

VL - 89-90

SP - 539

EP - 543

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

ER -